Promontory Therapeutics Inc. is a clinical stage pharmaceutical company developing small molecule immunotherapies. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death as well as osteotropism that confers advantages indealing with cancers that originate in or metastasize to the bone. Clinical data generated to date across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability proﬁle, and three Phase 2 studies of PT-112 are underway. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pﬁzer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active collaborative research and development agreement (CRADA) with the NCI to conduct a Phase 2 trial utilizing PT-112 in thymic epithelial tumors.

Biotechnology

Pharmaceutical

Promontory Therapeutics

Matthew Price

Jesse Borgese

Tyler Ames

Marie-Therese Hehenberger

Mariam Mahbob, CCRP

Johan Baeck

Helene Shea

Elodie Benard, MS, CCRP-PM

Aamena Chaudhry

Leadership Team

Research and Development

Clinical Operations

Teams at Promontory Therapeutics

Leadership Team

Research and Development

Clinical Operations